Current Treatment Options in Oncology

, Volume 9, Issue 2, pp 180–190

Peritoneal Mesothelioma

  • Mary E. Hesdorffer
  • John Chabot
  • Carolyn DeRosa
  • Robert Taub
Malignant Mesothelioma

DOI: 10.1007/s11864-008-0072-2

Cite this article as:
Hesdorffer, M.E., Chabot, J., DeRosa, C. et al. Curr. Treat. Options in Oncol. (2008) 9: 180. doi:10.1007/s11864-008-0072-2

Opinion statement

Malignant peritoneal mesothelioma (MPM) is an aggressive neoplasm that rapidly spreads within the confines of the abdominal cavity to involve most accessible peritoneal and omental surfaces. Current treatment options are unsatisfactory, and new approaches are needed. Recent publications have reported improved survival with an intensive loco-regional treatment strategy including cytoreductive surgery (CRS) along with hyperthermic intraperitoneal chemotherapy (HIPEC). We have noted at our institution prolonged survival in selected patients after intensive multimodality treatment. Our most recently reported trial included initial laparatomy with omentectomy, resection of peritoneal implants, and placement of bilateral peritoneal Portacath; repeated courses of intraperitoneal chemotherapy with doxorubicin, cisplatin, and interferon gamma; second-look laparotomy; and intraoperative hyperthermic perfusion with mitomycin and cisplatin, followed by whole abdominal radiation. To date there have been no universally accepted treatments for MPM. Unless referred to a specialty center, patients are routinely treated with pemetrexed and cisplatin which has been shown to increase survival in pleural mesothelioma.

Copyright information

© Current Medicine Group LLC 2008

Authors and Affiliations

  • Mary E. Hesdorffer
    • 1
  • John Chabot
    • 2
  • Carolyn DeRosa
    • 2
  • Robert Taub
    • 2
  1. 1.Mesothelioma Applied Research FoundationSanta BarbaraUSA
  2. 2.Herbert Irving Comprehensive Cancer Center, College of Physicians and Surgeons, Columbia UniversityNew YorkUSA